Clinical trial · Interventional
Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation
Role of SPECT in Radiotherapy Treatment Planning and Toxicity Evaluation for the Patients With Stage I-III NSCLC
NCT01745484CI-TRIAL-00038334completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Overall objective of the study is to compare the use of SPECT in radiotherapy treatment planning with standard CT-based radiotherapy for stage I-III non-small-cell lung cancer patients
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small-cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Radiation Pneumonitis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SPECT-based treatment plan | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm 1
- description
- SPECT scan will be performed at baseline. Patients will receive radiotherapy according to standard CT-based plan with conventional dose-volume histogram
- interventionNames
- Other: SPECT-based treatment plan
Primary outcomes (1)
- measure
- Grade 2 radiation pneumonitis
- timeFrame
- measured 0-12 months after completed radiotherapy
- description
- The primary endpoint is grade 2 pneumonitis, defined according to the NCI Common Toxicity Criteria for Adverse Events (CTC) version 4.0. Estimation of the occurrence of pulmonary tissue effects: Number of patients developing pulmonary toxicity over grade 2 in both treatment arms according to the Common Terminology Criteria for Adverse Events CTC v. 4.0 and measured serially from 0 to 12 months after radiotherapy, as well as according to the SOMA-LENT scale measured serially from 0 to 12 months after radiotherapy
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Stage I-III non-small cell lung cancer, histologically verified * Referred for definitive radiotherapy to the Department of Oncology, Aarhus University Hospital * Meet the criteria for curatively intended radiotherapy described in details in the national guidelines * Concurrent chemotherapy is accepted * Adults over 18, that have given oral and written informed consent before patient registration * The patients can only be randomized in this trial once Exclusion Criteria: * other uncontrolled malignancies * human albumin allergy * any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
References
Publications (0)
Data not yet available
No reference posted for this study.